Pluristem Therapeutics (PSTI) & Protagonist Therapeutics (PTGX) Head to Head Comparison
Pluristem Therapeutics (NASDAQ: PSTI) and Protagonist Therapeutics (NASDAQ:PTGX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.
Volatility and Risk
Pluristem Therapeutics has a beta of 0.09, meaning that its share price is 91% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of -1.66, meaning that its share price is 266% less volatile than the S&P 500.
This table compares Pluristem Therapeutics and Protagonist Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Pluristem Therapeutics||$2.85 million||55.76||-$27.81 million||($0.32)||-4.59|
|Protagonist Therapeutics||N/A||N/A||-$37.17 million||($2.69)||-6.87|
Pluristem Therapeutics has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Pluristem Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
4.3% of Pluristem Therapeutics shares are held by institutional investors. Comparatively, 39.7% of Protagonist Therapeutics shares are held by institutional investors. 7.0% of Pluristem Therapeutics shares are held by insiders. Comparatively, 15.5% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This is a breakdown of current ratings for Pluristem Therapeutics and Protagonist Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Pluristem Therapeutics presently has a consensus target price of $4.38, indicating a potential upside of 197.62%. Protagonist Therapeutics has a consensus target price of $39.50, indicating a potential upside of 113.86%. Given Pluristem Therapeutics’ higher possible upside, analysts plainly believe Pluristem Therapeutics is more favorable than Protagonist Therapeutics.
This table compares Pluristem Therapeutics and Protagonist Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Pluristem Therapeutics beats Protagonist Therapeutics on 6 of the 10 factors compared between the two stocks.
About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company’s products include PLX-PAD and PLX R18. The Company’s PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company’s PLX products are administered using a standard needle and syringe. The Company’s PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women’s health diseases.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn’s disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.
Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.